
According to data from Benzinga Pro, during Q4, UroGen Pharma's (NASDAQ:URGN) reported sales totaled $16.17 million. Despite a 5.82% increase in earnings, the company posted a loss of $28.45 million. UroGen Pharma collected $11.35 million in revenue during Q3, but reported earnings showed a $30.21 million loss.